tradingkey.logo

PAVmed Inc

PAVM
10.800USD
+0.220+2.08%
Cierre 02/06, 16:00ETCotizaciones retrasadas 15 min
8.30MCap. mercado
PérdidaP/E TTM

Más Datos de PAVmed Inc Compañía

PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.

Información de PAVmed Inc

Símbolo de cotizaciónPAVM
Nombre de la empresaPAVmed Inc
Fecha de salida a bolsaJul 27, 2016
Director ejecutivoAklog (Lishan)
Número de empleados39
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 27
Dirección360 Madison Avenue
CiudadNEW YORK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal10017
Teléfono12129494319
Sitio Webhttps://pavmed.com/
Símbolo de cotizaciónPAVM
Fecha de salida a bolsaJul 27, 2016
Director ejecutivoAklog (Lishan)

Ejecutivos de PAVmed Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
7.62K
--
Mr. Michael J. Glennon
Mr. Michael J. Glennon
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
7.56K
-166.00%
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
7.17K
--
Mr. Sundeep Agrawal, M.D.
Mr. Sundeep Agrawal, M.D.
Director
Director
5.41K
--
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Ms. Debra J. White
Ms. Debra J. White
Independent Director
Independent Director
--
--
Mr. Timothy (Tim) Baxter
Mr. Timothy (Tim) Baxter
Independent Director
Independent Director
--
--
Mr. Shaun M. O'Neil
Mr. Shaun M. O'Neil
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Mr. Michael A. Gordon
Mr. Michael A. Gordon
General Counsel, Secretary
General Counsel, Secretary
--
--
Mr. Matt Riley
Mr. Matt Riley
Director of Investor Relations
Director of Investor Relations
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
7.62K
--
Mr. Michael J. Glennon
Mr. Michael J. Glennon
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
7.56K
-166.00%
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
7.17K
--
Mr. Sundeep Agrawal, M.D.
Mr. Sundeep Agrawal, M.D.
Director
Director
5.41K
--
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Ms. Debra J. White
Ms. Debra J. White
Independent Director
Independent Director
--
--

Desglose de ingresos

La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.

Estadísticas de accionistas

Actualizado: sáb., 7 de feb
Actualizado: sáb., 7 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Tasso Partners, LLC
8.62%
Sargent Investment Group, LLC
3.37%
First Manhattan Co. LLC
2.39%
Dubreville (Anthony Michael)
2.03%
The Vanguard Group, Inc.
1.15%
Otro
82.45%
Accionistas
Accionistas
Proporción
Tasso Partners, LLC
8.62%
Sargent Investment Group, LLC
3.37%
First Manhattan Co. LLC
2.39%
Dubreville (Anthony Michael)
2.03%
The Vanguard Group, Inc.
1.15%
Otro
82.45%
Tipos de accionistas
Accionistas
Proporción
Corporation
9.62%
Investment Advisor
8.36%
Individual Investor
7.99%
Research Firm
0.65%
Investment Advisor/Hedge Fund
0.55%
Hedge Fund
0.34%
Venture Capital
0.04%
Otro
72.45%

Participación institucional

Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
60
96.72K
9.71%
+34.80K
2025Q3
89
2.39M
8.50%
+565.99K
2025Q2
101
5.16M
29.26%
+2.76M
2025Q1
106
5.16M
31.74%
+3.03M
2024Q4
110
2.41M
17.67%
+156.53K
2024Q3
120
2.58M
24.42%
+197.13K
2024Q2
133
1.94M
20.61%
-301.78K
2024Q1
169
2.19M
26.52%
+433.78K
2023Q4
185
1.60M
20.86%
-48.73K
2023Q3
208
1.30M
18.00%
-268.87K
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Tasso Partners, LLC
85.81K
8.62%
+85.81K
--
Feb 21, 2025
Sargent Investment Group, LLC
33.54K
3.37%
+33.54K
--
Jul 01, 2025
First Manhattan Co. LLC
23.80K
2.39%
--
--
Sep 30, 2025
Dubreville (Anthony Michael)
20.21K
2.03%
+20.21K
--
Aug 30, 2024
The Vanguard Group, Inc.
6.95K
0.7%
+4.23K
+155.74%
Sep 30, 2025
Pavilion Venture Partners, L.L.C.
9.90K
0.99%
--
--
Oct 23, 2025
Aklog (Lishan)
7.62K
0.77%
--
--
Oct 23, 2025
Glennon (Michael J)
7.56K
0.76%
-166.00
-2.15%
Oct 23, 2025
White (Debra Jayne)
7.17K
0.72%
--
--
Oct 23, 2025
Ver más

ETFs relacionados

Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Fecha ex-dividendo
Tipo
Relación
Dec 30, 2025
Merger
30→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Dec 30, 2025
Merger
30→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
KeyAI